WVE - WaVe Life Sciences Ltd Stock Price, Fair Value and News

$13.51+0.32 (+2.43%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

WVE Price Action

Last 7 days

0.5%

Last 30 days

-5.3%

Last 90 days

137.9%

Trailing 12 Months

168.6%

WVE RSI Chart

WVE Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-14.46

Price/Sales (Trailing)

18.65

EV/EBITDA

-12.64

Price/Free Cashflow

-14.53

WVE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

WVE Fundamentals

WVE Revenue

Revenue (TTM)

110.5M

Rev. Growth (Yr)

-10.92%

Rev. Growth (Qtr)

57.06%

WVE Earnings

Earnings (TTM)

-142.5M

Earnings Growth (Yr)

-951.9%

Earnings Growth (Qtr)

-87.65%

WVE Profitability

EBT Margin

-128.97%

Return on Equity

-100.62%

Return on Assets

-39.75%

Free Cashflow Yield

-6.88%

WVE Investor Care

Shares Dilution (1Y)

53.98%

Diluted EPS (TTM)

-1.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	112.9M	110.5M	0	0
2023	14.8M	36.6M	85.5M	113.3M
2022	42.7M	40.3M	4.2M	3.6M
2021	0	18.7M	52.1M	50.4M
2020	17.1M	12.5M	13.0M	20.1M
2019	16.0M	18.8M	17.2M	16.0M
2018	4.9M	8.7M	11.9M	14.4M
2017	1.9M	2.5M	3.5M	3.9M
2016	0	543.0K	809.0K	1.5M
2015	0	0	0	152.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About WaVe Life Sciences Ltd

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

CEO	Dr. Paul B. Bolno M.B.A., M.D., MBA
WEBSITE	wavelifesciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	250

WaVe Life Sciences Ltd Frequently Asked Questions

What is the ticker symbol for WaVe Life Sciences Ltd? What does WVE stand for in stocks?

WVE is the stock ticker symbol of WaVe Life Sciences Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of WaVe Life Sciences Ltd (WVE)?

As of Fri Dec 20 2024, market cap of WaVe Life Sciences Ltd is 2.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WVE stock?

You can check WVE's fair value in chart for subscribers.

Is WaVe Life Sciences Ltd a good stock to buy?

The fair value guage provides a quick view whether WVE is over valued or under valued. Whether WaVe Life Sciences Ltd is cheap or expensive depends on the assumptions which impact WaVe Life Sciences Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WVE.

What is WaVe Life Sciences Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, WVE's PE ratio (Price to Earnings) is -14.46 and Price to Sales (PS) ratio is 18.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WVE PE ratio will change depending on the future growth rate expectations of investors.